Your browser doesn't support javascript.
loading
Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.
Nalisa, David Lubasi; Cuboia, Nelson; Dyab, Eman; Jackson, Idongesit Linus; Felix, Habimana Jean; Shoki, Pantaleon; Mubiana, Mary; Oyedeji-Amusa, Mariam; Azevedo, Luís; Jiang, Hongwei.
Afiliación
  • Nalisa DL; Department of Metabolism and Endocrinology, Endocrine and Metabolic Disease Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
  • Cuboia N; Adult Hospital Internal Medicine Department, Endocrine Unit, The University Teaching Hospitals, Lusaka, Zambia.
  • Dyab E; Center for Health Technology and Service Research (CINTESIS) & Health Research Network Associated Laboratory (RISE), University of Porto, Porto, Portugal.
  • Jackson IL; Pharmaceutics Department, Faculty of Pharmacy, University of Tripoli, Tripoli, Libya.
  • Felix HJ; Department of Clinical Pharmacy and Biopharmacy, Faculty of Pharmacy, University of Uyo, Uyo, Akwa Ibom State, Nigeria.
  • Shoki P; Directorate of Research and Community Health-Ruli Higher Institute of Health -Saint Rose de Lima (RHIH), Kigali, Rwanda.
  • Mubiana M; Business Development and Partnership, CLM Consultants Ltd., Dar es Salaam, Tanzania.
  • Oyedeji-Amusa M; Department of Disease Control, School of Veterinary Medicine, University of Zambia, Lusaka, Zambia.
  • Azevedo L; Department of Botany and Plant Biotechnology, University of Johannesburg, Johannesburg, South Africa.
  • Jiang H; Center for Health Technology and Service Research (CINTESIS) & Health Research Network Associated Laboratory (RISE), University of Porto, Porto, Portugal.
Front Endocrinol (Lausanne) ; 15: 1309118, 2024.
Article en En | MEDLINE | ID: mdl-38440786
ABSTRACT

Background:

Overweight and obesity are increasing global public health problems. Mazdutide is a new dual agonist drug that can potentially reduce weight and blood glucose levels simultaneously. However, the synthesis of evidence on the efficacy and safety of this drug is scarce. Therefore, this study aimed to synthesize evidence on the efficacy and safety of Mazdutide compared to placebo on weight reduction among adults with and without diabetes.

Methods:

We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs). Data were retrieved from six electronic databases PubMed, Web of Science, Scopus, Cochrane Library, ClinicalTrial.gov, and Google Scholar, and manually searched from the included references. The data were synthesized using a random effect model. This analysis was performed in the R programming language using the Meta package.

Results:

A total of seven RCTs involving 680 participants were included in this study. Mazdutide was more effective in reducing body weight (mean difference [MD]= -6.22%, 95% confidence interval [CI] -8.02% to -4.41%, I2 = 90.0%), systolic blood pressure (MD = -7.57 mmHg, 95% CI -11.17 to -3.98 mmHg, I2 = 46%), diastolic blood pressure (MD = -2.98 mmHg, 95% CI -5.74 to -0.22 mmHg, I2 = 56%), total cholesterol (MD = -16.82%, 95% CI -24.52 to -9.13%, I2 = 61%), triglycerides (MD = -43.29%, 95% CI -61.57 to -25.01%, I2 = 68%), low-density lipoprotein (MD= -17.07%, 95% CI -25.54 to -8.60%, I2 = 53%), and high-density lipoprotein (MD = -7.54%, 95% CI -11.26 to -3.83%, I2 = 0%) than placebo. Mazdutide was associated with reduced hemoglobin A1c (HbA1c) and fasting plasma glucose in participants with type 2 diabetes. In the subgroup and meta-regression analyses, weight reduction was more significant in non-diabetics compared to diabetics, and in those who received a longer treatment duration (24 weeks) than in those on shorter durations (12-20 weeks). Participants who received Mazdutide had a higher risk of transient mild or moderate gastrointestinal side effects.

Conclusion:

Mazdutite appears to be effective in weight reduction among patients with and without diabetes, and it has an advantage over other associated comorbidities. However, it was associated with mild or moderate gastrointestinal side effects. Systematic review registration https//www.crd.york.ac.uk/prospero/display_record.php?RecordID=403859, identifier CRD42023403859.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptidos / Pérdida de Peso / Diabetes Mellitus Tipo 2 Límite: Humans Idioma: En Revista: Front Endocrinol (Lausanne) Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptidos / Pérdida de Peso / Diabetes Mellitus Tipo 2 Límite: Humans Idioma: En Revista: Front Endocrinol (Lausanne) Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza